Top 10 Lemborexant (Dayvigo) Generic Manufacturers in Australia
The pharmaceutical industry in Australia has experienced significant growth, particularly in the generics market, which accounts for approximately 30% of the total pharmaceutical market. As of 2023, the Australian generic medicines market was valued at around AUD 1.8 billion, reflecting a robust demand for affordable medications, such as Lemborexant, commonly known by its brand name Dayvigo, used in the treatment of insomnia. The increasing prevalence of sleep disorders and the rising cost of branded medications are driving the growth of the generics sector in Australia.
1. Apotex Australia Pty Ltd
Apotex is one of the largest generic pharmaceutical companies in Australia, holding a significant market share of approximately 7.5%. The company produces over 300 generic medications, including Lemborexant, and has a production facility capable of manufacturing around 5 million units annually.
2. Mylan Australia
Mylan, now part of Viatris, is a leading player in the Australian generics market, with a market share close to 6%. Mylan’s manufacturing capabilities enable the production of millions of tablets and capsules each year, including generic formulations of Lemborexant, ensuring robust competition in the sleep aid segment.
3. Sandoz Australia
Sandoz, a division of Novartis, holds a market share of about 5% in the Australian generics market. Their extensive portfolio includes over 1,000 generic medicines, and they produce Lemborexant in large volumes, contributing significantly to the accessibility of this medication across Australia.
4. Sigma Pharmaceuticals
Sigma Pharmaceuticals has a market share of around 4.5% in the generics sector. With a production capacity of over 3 million units per year, they are a key supplier of Lemborexant generics, focusing on delivering high-quality products to the Australian market.
5. Hetero Labs Limited
Hetero Labs, an Indian pharmaceutical company with a growing presence in Australia, holds approximately 3% of the market share. They manufacture Lemborexant under strict quality controls and have been increasing their output, with an annual production capability of over 2 million units.
6. Fresenius Kabi Australia
Fresenius Kabi is known for its focus on specialty pharmaceuticals and generics, holding a market share of around 2.5%. The company produces Lemborexant in compliance with international standards, and their production facility is capable of manufacturing over 1.5 million units per year.
7. AFT Pharmaceuticals
AFT Pharmaceuticals holds a market share of about 2%, focusing on innovative and generic medications. They have successfully introduced Lemborexant into their portfolio and maintain production capabilities that support the growing demand for sleep aids in Australia.
8. Starpharma Holdings Limited
Starpharma, while primarily known for its innovative drug delivery systems, is also making strides in the generics space, with a market share close to 1.5%. Their recent ventures into Lemborexant production reflect a strategic move to expand their footprint in the pharmaceutical market.
9. Chemist Warehouse
Chemist Warehouse, although primarily a retail pharmacy chain, has its own line of generic medications, including Lemborexant. With a market share of approximately 1%, they leverage their extensive retail presence to ensure that generics reach consumers efficiently.
10. Generic Partners
Generic Partners is a smaller yet notable player in the Australian generics market, with a market share of around 1%. They focus on providing cost-effective alternatives to branded medications, including Lemborexant, and have a production capacity of over 1 million units annually.
Insights
The generics market for Lemborexant in Australia is poised for continued growth, driven by an increasing prevalence of insomnia and the ongoing push for cost-effective medications. The Australian government’s commitment to expanding the accessibility of generics and reducing healthcare costs fuels this trend, with the generics market projected to grow at a CAGR of 5% over the next five years. Additionally, as healthcare providers and patients seek more affordable alternatives to branded medications, the competitive landscape among manufacturers will likely intensify, leading to innovations in production and distribution strategies. With generics accounting for a substantial portion of the pharmaceutical market, firms that adapt to these trends will be well-positioned for success.
Related Analysis: View Previous Industry Report
